secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2022-02-02T23:59:59+00:00
Accession:  0001193125-22-025772
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences terminates patent license agreement with NIAID, effective April 2, 2022
--------------------------------------------------------------------------------

- Terminated Patent License Agreement with National Institute of Allergy and Infectious Diseases (NIAID).
- Termination effective April 2, 2022.
- Company will have no future payment obligations under the Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312522025772/0001193125-22-025772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312522025772/d303337d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-025772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer